Long-term serological follow-up of blood donors with an HTLV-indeterminate western blot: antibody profile of seroconverters and individuals with false reactions.

The high proportion of indeterminate results of the screening test for human T-lymphotropic virus (HTLV) infection has been a challenge worldwide. In this study, 60 persons with seroindeterminate results for HTLV were followed until their serological status was defined. At least two independent serological tests (EIA and WB) from sequential samples were performed at an average interval of 4.

HTLV-2 horizontal and vertical transmission in a family from a Brazilian urban area: seroepidemiological, clinical and molecular study.

Human T cell lymphotropic virus type 2 (HTLV-2) has been shown to be endemic in Brazilian Indians and among intravenous drug users in urban areas, but transmission of this infection seems to be infrequent in the general population living in urban areas in Brazil. Six persons in three generations of a Brazilian family were evaluated to assess HTLV-2 transmission and its molecular features in the positive cases. The index was detected during screening (HTLV EIA) of donated blood in Fundação Hemominas, Belo Horizonte, Brazil.

Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil.

Brazil may have the highest absolute number of HTLV-I/II seropositive individuals in the world. Screening potential blood donors for HTLV-I/II is mandatory in Brazil. The public blood center network accounts for about 80.

HTLV-I/II and blood donors: determinants associated with seropositivity in a low risk population.

Objective: Blood donors in Brazil have been routinely screened for HTLV-I/II since 1993. A study was performed to estimate the prevalence of HTLV-I/II infection in a low risk population and to better understand determinants associated with seropositivity.

Methods: HTLV-I/II seropositive (n=135), indeterminate (n=167) and seronegative blood donors (n=116) were enrolled in an open prevalence prospective cohort study.